Research ArticlePDA Paper
Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products
Stan Bukofzer, John Ayres, Anna Chavez, Minerva Devera, Jahanvi Miller, Douglas Ross, John Shabushnig, Susan Vargo, Harry Watson and Rick Watson
PDA Journal of Pharmaceutical Science and Technology January 2015, 69 (1) 123-139; DOI: https://doi.org/10.5731/pdajpst.2015.01037
Stan Bukofzer
MD
Roles: Hospira, Inc (Chair)
John Ayres
MD
Roles: Eli Lilly and Company
Anna Chavez
MD
Roles: Baxter
Minerva Devera
DBA, QSM
Roles: Emergent
Jahanvi Miller
MBA
Roles: Parenteral Drug Association (PDA)
Douglas Ross
MD
Roles: Pfizer
John Shabushnig
PhD
Roles: Insight Pharma Consulting, LLC
Susan Vargo
MS, PhD
Roles: Amgen
Harry Watson
MTSC
Roles: CMQ/OE, Hospira, Inc
Rick Watson
Roles: Merck

References
- 1.↵
Injectable Drug Delivery: Probing the Route to Growth. Datamonitor, January 2004. http://www.datamonitor.com/Products/Free/Report/DMHC1964/010DMHC1964.pdf (accessed July 9, 2014).
- 2.↵
General Chapter <790> Visible Particulates in Injections. USP 37/NF 32; U.S. Pharmacopeia: 2014. www.usp.org.
- 3.↵
- Lynn S.
- 4.↵
EudraLex, Inspections. An Analysis of Quality Product Defects in the Centralised Procedure; European Commission: 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004420.pdf (accessed July 9, 2014).
- 5.↵
EudraLex, Standard Operating Procedure—Annex 4, Crisis Management Regarding Defects of Centrally Authorised Products: Classification of Batch Recalls for Quality Defects; European Commission: 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004404.pdf (accessed June 30, 2014).
- 6.↵
MHRA Drug Alerts website. http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/index.htm (accessed June 30, 2014).
- 7.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Fybogel Hi-Fibre and Fybogel Orange manufactured by Reckitt Benckiser Healthcare (UK) Limited (EL (14)A/08). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON426907 (accessed June 30, 2014).
- 8.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Fybogel Orange—Reckitt Benckiser Healthcare (UK) Limited (EL (14)A/04). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON392875 (accessed June 30, 2014).
- 9.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Clarithromycin 500mg Powder for Solution for Infusion in Agila livery manufactured by Strides Arcolab International Limited (EL (14)A/07). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON426899 (accessed June 30, 2014).
- 10.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Vancomycin Powder for Concentrate for Solution for Infusion manufactured by Actavis Group PTC ehf (EL (14)A/06). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON425132 (accessed June 30, 2014).
- 11.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Viread 245 mg Film-Coated Tablets—Gilead Sciences Limited (EL (14)A/03). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON391205 (accessed June 30, 2014).
- 12.↵
U.S. Code of Federal Regulations Title 21 Part 7.3(m): Definitions. ecfr.gpoaccess.gov (accessed Sep. 2, 2014).
- 13.↵
- 14.↵
- Dempsey G.
- 15.↵
- 16.↵
- Backhouse C. M.,
- Ball P. R.,
- Booth S.,
- Kelshaw M. A.,
- Potter S. R.,
- McCollum C. N.
- 17.↵
U.S. Food and Drug Administration (FDA). Multiple product recall notifications, 2009–2012. http://www.fda.gov/Drugs/DrugSafety/DrugRecalls/default.htm (accessed March–April 2012).
- 18.↵
FDA Recalls, Market Withdrawals, and Safety Alerts. Bedford Laboratories Issues a Voluntary Nationwide Patient Level Recall of Acetylcysteine Solution, USP, LOT 1877093. Press release, February 2, 2012. http://www.fda.gov/Safety/Recalls/ucm290204.htm (accessed June 19, 2014).
- 19.↵
FDA Recalls, Market Withdrawals, & Safety Alerts. American Regent Initiates Nationwide Voluntary Recall of Methyldopate HCL Injection, USP 5 mL Single Dose Vial Due to Glass Particulates. Press release, June 6, 2011. http://www.fda.gov/Safety/Recalls/ucm258064.htm (accessed June 19, 2014).
- 20.↵
FDA Recalls, Market Withdrawals, and Safety Alerts. American Regent Initiates Nationwide Voluntary Recall of Caffeine & Sodium Benzoate Injection, USP 250 mg/mL, 2 mL Single Dose Vial Due to Visible Particulates. Press release, May 5, 2011. http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2011/ucm254287.htm (accessed June 19, 2014).
- 21.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 4 Drug Alert: B.Braun Medical Ltd—NuTRIflex Lipid Products (EL (11)A/32). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON137913 (accessed June 19, 2014).
- 22.↵
MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Drug Alert (Action within 48 hours): Abraxis BioScience Ltd—Abraxane 5mg/ml powder for suspension for infusion (EL (09)A/28). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON062632 (accessed June 19, 2014).
- 23.↵
- 24.↵
- Lehr H.-A.,
- Brunner J.,
- Rangoonwala R.,
- Kirkpatrick C. J.
- 25.↵
- Macdougall I. C.,
- Roger S. D.,
- de Francisco A.,
- Goldsmith D. J. A.,
- Schellekens H.,
- Ebbers H.,
- Jelkmann W.,
- London G.,
- Casadevall N.,
- Hörl W. H.,
- Kemeny D. M.,
- Pollock C.
- 26.↵
- 27.↵
- Carpenter J. F.,
- Randolph T. W.,
- Jiskoot W.,
- Crommelin D, J.,
- Middaugh R. C.,
- Winter G.,
- Fan Y.-X.,
- Kirshner S.,
- Verthely I, D.,
- Kozlowski S.,
- Clouse K. A.,
- Swann P. G.,
- Roseberg A.,
- Cherney B.
- 28.↵
- Watson R.,
- Strab J.
- 29.↵
- Brewer J. H.,
- Dunning J. H. F.
- 30.↵
- Stehbens W.E.,
- Florey H.W.
- 31.↵
- Schoenberg M.D.,
- Gilman P.A.,
- Mumaw V.R.,
- Moore R.D.
- 32.↵
General Chapter <1> Injections. USP 36/NF 31; U.S. Pharmacopeia: 2013. www.usp.org.
- 33.↵
Chapter 2.9.20, Particulate Contamination: Visible Particles; European Pharmacopeia: 2013.
- 34.↵
Eudralex, Guideline on Production and Quality Control of Monoclonal Antibodies and Related Substances; European Commission: 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003073.pdf (accessed July 9, 2014).
- 35.↵
Chapter 6.06, Foreign Insoluble Matter Test for Injections; Japanese Pharmacopeia: 2011 http://db.yaozh.com/foreign/JP15/jp1/F1_70.pdf (accessed July 9, 2014).
- 36.↵
- Knapp J. Z,
- Kushner H. R.
- 37.↵
- Knapp J. Z,
- Kushner H. R.
- 38.↵
- Shabushnig J. G.,
- Melchore J. A.,
- Geiger M.,
- Chrai S.,
- Gerger M. E.
- 39.
General Chapter <788> Particulate Matter in Injections; USP 37/NF 32; U.S. Pharmacopeia: 2011. www.usp.org.
- 40.↵
Monograph for Monoclonal Antibodies for Human Use; European Pharmacopeia: 2013.
- 41.↵
Circulaire N°10-0224 Direction Des Affaires Scientifiques, Pharmaceutiques Et Medicales AFSSAPS Form n° 2 – Complaints “glass particles in injectable products,” (Notification of “glass particles in injectable products”) April 19, 2010.
- 42.↵
- Mirtallo J.,
- Canada T.,
- Johnson D.,
- Kumpf V.,
- Petersen C.,
- Sacks G.,
- Seres D.,
- Guenter P.
- 43.↵
- 44.↵
- Borchert S. J.,
- Abe A.,
- Aldrich S. D.,
- Fox L. E.,
- Freeman J. E.,
- White R. D.
- 45.↵
- Groves M. J.,
- De Malka S. R.
- 46.↵
- Groves M. J.
- 47.↵
- Groves M. J.
- 48.↵
- Langille S. E.
- 49.↵
- 50.↵
- Cho M.,
- Cho W.-S.,
- Choi M.,
- Kim S. J.,
- Han B. S.,
- Kim S. H.,
- Kim H. O.,
- Sheen Y. Y.,
- Jeong J.
- 51.↵
- Hozumi K.,
- Kitamura K.,
- Kitade T.,
- Iwagami S.
- 52.↵
- Hay J.
- 53.↵
- Miliauskas J. R.,
- Mukherjee T.,
- Dixon. B.
- 54.↵
- Greenblatt D.,
- Divoll-Allen M.
- 55.↵
- 56.↵
- 57.↵
- Akers M. J.,
- Larrimore D. S.,
- Guazzo D. M.
- 58.↵
- Niden A. H.,
- Aviado D. M.
- 59.↵
- Groom R. C.,
- Quinn R. D.,
- Lennon P.,
- Donegan D. J.,
- Braxton J. H.,
- Kramer R. S.,
- Weldner P. W.,
- Russo L.,
- Blank S. D.,
- Christie A. A.,
- Taenzer A. H.,
- Forest R. J.,
- Clark C.,
- Welch J.,
- Ross C. S.,
- O'Connor G. T.,
- Likosky D. S.
- 60.↵
- Blauth C. I.
- 61.↵
- Stump D. A.,
- Rogers A. T.,
- Hammon J. W.,
- Newman S. P.
- 62.↵
- Liu Y.-H.,
- Wang D.-X.,
- Li L.-H.,
- Wu X.-M.,
- Shan G.-J.,
- Su Y.,
- Li J.,
- Yu Q.-J.,
- Shi C.-X.,
- Huang Y.-N.,
- Sun W.
- 63.↵
- Liu J.-F.,
- Su Z.-K.,
- Ding W.-X.
- 64.↵
- Schoenberg M. D.,
- Gilman P. A.,
- Mumaw V.,
- Moore R. D.
- 65.↵
- Brekkan A.,
- Lexow P. E.,
- Woxholt G.
- 66.↵
- 67.↵
- Jones M. L.,
- Warren J. S.
- 68.↵
- 69.↵
- Garvan J. M.,
- Gunner B. W.
- 70.↵
- Garvan J. M.,
- Gunner B.W.
- 71.↵
- Hill S. E.,
- Heldman L. S.,
- Goo E. D. H.,
- Whippo P. E.,
- Perkinson J. C.
- 72.↵
- Reedy J. S.,
- Kuhlman J. E.,
- Voytovich M.
- 73.↵
- Burton J. F.,
- Zawadzki E. S.,
- Wetherell H. R.,
- Moy T. W.
- 74.↵
- Douglas F. G.,
- Kafilmount K. J.,
- Patt N. L.
- 75.↵
- 76.↵
- 77.↵
- Jorens P. G.,
- Van Marck E.,
- Snoeckx A.,
- Parizel P. M.
- 78.↵
- Kringsholm B.,
- Christoffersen P.
- 79.↵
- Baydur A.,
- Koss M. N.,
- Sharma O. P.,
- Dalgleish G. E.,
- Nguyen D. V.,
- Mullick F. G.,
- Murakata L. A.,
- Centeno J. A.
- 80.↵
- Wijeyaratne S. M.,
- Ubayasiri R. A.,
- Weerasinghe C.
- 81.↵
- Brown K. T.
- 82.↵
- Plasencia A. R.,
- Santillan A.
- 83.↵
- 84.↵
- 85.↵
- 86.↵
- 87.↵
- Shannon P.,
- Billbao J.M.,
- Marotta T.,
- Terbrugge K.
- 88.↵
Technical Report No 44: Quality Risk Management for Aseptic Processes; Parenteral Drug Association: 2008. https://store.pda.org/ProductCatalog/Product.aspx?ID=1220 (Accessed July 21, 2014).
- 89.↵
Quality Guideline Q9: Quality Risk Management; International Conference on Harmionisation: 2005. www.ich.org (accessed March 11, 2014).
- 90.↵
- Newton D. W.,
- Driscoll D. F.
- 91.↵
- Allcutt D. A.,
- Lort D.,
- McCollum C. N.
- 92.↵
- Kweder S.
- 93.↵
- Parikh M. J.,
- Dumas G.,
- Silvestri A.,
- Bistrian B. R.,
- Driscoll D. F.
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 69, Issue 1
January/February 2015
Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products
Stan Bukofzer, John Ayres, Anna Chavez, Minerva Devera, Jahanvi Miller, Douglas Ross, John Shabushnig, Susan Vargo, Harry Watson, Rick Watson
PDA Journal of Pharmaceutical Science and Technology Jan 2015, 69 (1) 123-139; DOI: 10.5731/pdajpst.2015.01037
Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products
Stan Bukofzer, John Ayres, Anna Chavez, Minerva Devera, Jahanvi Miller, Douglas Ross, John Shabushnig, Susan Vargo, Harry Watson, Rick Watson
PDA Journal of Pharmaceutical Science and Technology Jan 2015, 69 (1) 123-139; DOI: 10.5731/pdajpst.2015.01037
Jump to section
Related Articles
- No related articles found.
Cited By...
- Identification and Root Cause Analysis of the Visible Particles Commonly Encountered in the Biopharmaceutical Industry
- Applying Machine Learning to the Visual Inspection of Filled Injectable Drug Products
- Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations
- Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals
- Achieving "Zero" Defects for Visible Particles in Injectables
- Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial
- A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products
- Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products
- Filtration of Glass Delamination Particles with West Pharmaceutical Vial Adapters